White Paper: The Role of rasH2 in an Evolving Pharmaceutical Carcinogenicity LandscapeFor over 40 years, the 2-year rodent bioassay has been the regulatory standard to determine the tumorigenic potential of novel pharmaceuticals.

Recent retrospective analyses of multiple carcinogenicity datasets have indicated that the lifetime (2-year) bioassay does not always provide further value to the carcinogenicity risk assessment.

As a result, changes to the ICH S1 guidelines have been proposed with the potential to transform how pharmaceutical carcinogenicity evaluations are conducted.

Download this White Paper to learn:

  • The background and limitations of existing carcinogenicity testing protocols

  • The proposed changes to ICH S1 guidelines and their potential impact

  • How the rasH2 transgenic mouse model can facilitate carcinogenicity testing protocols to meet these new proposed guidelines

Complete the Form to Download Your Copy »

Get Your Copy Now!

   
© 2019 Taconic Biosciences, Inc. All rights reserved.

© 2019 Taconic Biosciences, Inc. All rights reserved.